{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:32:22Z","timestamp":1789590742174,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1124\/dmd.122.000967","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T18:40:13Z","timestamp":1677609613000},"page":"1127-1135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Emerging Roles of Uremic Toxins and Inflammatory Cytokines in the Alteration of Hepatic Drug Disposition in Patients with Kidney Dysfunction"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-7646","authenticated-orcid":false,"given":"Hiroshi","family":"Arakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-5679","authenticated-orcid":false,"given":"Yukio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.000967_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0026-895X(25)13247-1","article-title":"Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture","volume":"44","author":"Abdel-Razzak","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cpt.2102","article-title":"Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters","volume":"109","author":"Achour","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib3","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.freeradbiomed.2007.12.010","article-title":"Roles of nitric oxide in inflammatory downregulation of human cytochromes P450","volume":"44","author":"Aitken","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1124\/dmd.122.000967_bib4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib5","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.xphs.2017.03.013","article-title":"Inhibitory Effect of Crizotinib on Creatinine Uptake by Renal Secretory Transporter OCT2","volume":"106","author":"Arakawa","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.122.000967_bib6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00228-014-1709-7","article-title":"Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins","volume":"70","author":"Barnes","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cpt.983","article-title":"Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation","volume":"104","author":"Barnett","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/cts.12481","article-title":"Does Secretory Clearance Follow Glomerular Filtration Rate in Chronic Kidney Diseases? Reconsidering the Intact Nephron Hypothesis","volume":"10","author":"Chapron","year":"2017","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.122.000967_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cpt.445","article-title":"Transporters affecting biochemical test results: Creatinine-drug interactions","volume":"100","author":"Chu","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Collaboration","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/dmd.122.000967_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/dmd.109.029991","article-title":"Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure","volume":"38","author":"Dani","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1523-1755.2004.00354.x","article-title":"Characterization of uremic toxin transport by organic anion transporters in the kidney","volume":"65","author":"Deguchi","year":"2004","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.122.000967_bib14","doi-asserted-by":"crossref","first-page":"31185","DOI":"10.1074\/jbc.M110.107805","article-title":"Regulation of MRP2\/ABCC2 and BSEP\/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-alpha, IL-6, and IL-1beta","volume":"285","author":"Diao","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.000967_bib15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib16","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3390\/ijms15022538","article-title":"Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolism","volume":"15","author":"Dixon","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.122.000967_bib17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1681\/ASN.2011121175","article-title":"Normal and pathologic concentrations of uremic toxins","volume":"23","author":"Duranton","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.122.000967_bib18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0006-2952(98)00372-4","article-title":"Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy","volume":"57","author":"Elkahwaji","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11095-015-1785-0","article-title":"Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure","volume":"33","author":"Fujita","year":"2016","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.122.000967_bib22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2174\/1389200220666190402143125","article-title":"Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure","volume":"20","author":"Fujita","year":"2019","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.000967_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11095-013-1153-x","article-title":"Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans","volume":"31","author":"Fujita","year":"2014","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.122.000967_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0090-9556(24)13357-0","article-title":"Delayed elimination of SN-38 in cancer patients with severe renal failure","volume":"39","author":"Fujita","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bjp.0704951","article-title":"Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators","volume":"137","author":"Gu\u00e9vin","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib26","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1021\/acs.molpharmaceut.6b00332","article-title":"Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3","volume":"13","author":"Hsueh","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.122.000967_bib27","doi-asserted-by":"crossref","first-page":"38869","DOI":"10.1074\/jbc.M110.166686","article-title":"Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin","volume":"285","author":"Ito","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.000967_bib28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/bcp.12425","article-title":"Validation of 4\u03b2-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects","volume":"78","author":"Kasichayanula","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00280-017-3276-y","article-title":"Cooperative inhibitory effects of uremic toxins and other serum components on OATP1B1-mediated transport of SN-38","volume":"79","author":"Katsube","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib30","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1681\/ASN.2003090757","article-title":"Maladaptive role of IL-6 in ischemic acute renal failure","volume":"16","author":"Kielar","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.122.000967_bib31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00134-009-1430-7","article-title":"Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients","volume":"35","author":"Kirwan","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1124\/dmd.122.000967_bib32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1399-3089.2008.00478.x","article-title":"Clinical versatility of porcine hepatocytes in the light of interspecies differences in cytochrome P450 regulation and expression","volume":"15","author":"Kleine","year":"2008","journal-title":"Xenotransplantation"},{"key":"10.1124\/dmd.122.000967_bib33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/00498254.2017.1393582","article-title":"Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1","volume":"48","author":"Koide","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.000967_bib34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.2012.106","article-title":"OATP1B1 polymorphism as a determinant of erythromycin disposition","volume":"92","author":"Lancaster","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/dmd.107.016907","article-title":"Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta","volume":"36","author":"Le Vee","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1472-8206.2010.00822.x","article-title":"Regulation of drug transporter mRNA expression by interferon-\u03b3 in primary human hepatocytes","volume":"25","author":"Le Vee","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.108.023630","article-title":"Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6","volume":"37","author":"Le Vee","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1681\/ASN.V122326","article-title":"Downregulation of hepatic cytochrome P450 in chronic renal failure","volume":"12","author":"Leblond","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.122.000967_bib39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0090-9556(24)15079-9","article-title":"Decreased in vivo metabolism of drugs in chronic renal failure","volume":"28","author":"Leblond","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/11319980-000000000-00000","article-title":"CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications","volume":"49","author":"Lee","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.122.000967_bib41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.me.39.020188.002341","article-title":"Serum creatinine and renal function","volume":"39","author":"Levey","year":"1988","journal-title":"Annu Rev Med"},{"key":"10.1124\/dmd.122.000967_bib42","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.dmpk.2020.09.001","article-title":"6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients","volume":"35","author":"Masuo","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.122.000967_bib43","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1681\/ASN.2006010035","article-title":"Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure","volume":"17","author":"Michaud","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.122.000967_bib44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/cpt.757","article-title":"The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance","volume":"102","author":"Miners","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib45","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.1840220420","article-title":"Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture","volume":"22","author":"Muntan\u00e9-Relat","year":"1995","journal-title":"Hepatology"},{"key":"10.1124\/dmd.122.000967_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/CIRCULATIONAHA.118.034588","article-title":"Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling","volume":"139","author":"Nakano","year":"2019","journal-title":"Circulation"},{"key":"10.1124\/dmd.122.000967_bib47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/dmd.107.018192","article-title":"Effects of chronic renal failure on liver drug transporters","volume":"36","author":"Naud","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1124\/dmd.114.061317","article-title":"Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters","volume":"43","author":"Nguyen","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib49","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1158\/0008-5472.CAN-13-3634","article-title":"Influence of drug formulation on OATP1B-mediated transport of paclitaxel","volume":"74","author":"Nieuweboer","year":"2014","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.122.000967_bib50","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1681\/ASN.2009010082","article-title":"ESRD impairs nonrenal clearance of fexofenadine but not midazolam","volume":"20","author":"Nolin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.122.000967_bib51","doi-asserted-by":"crossref","first-page":"9237","DOI":"10.1038\/s41598-018-27672-y","article-title":"Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1","volume":"8","author":"Omote","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.122.000967_bib52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00228-018-2572-8","article-title":"The intact nephron hypothesis as a model for renal drug handling","volume":"75","author":"Pradhan","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.726669","article-title":"Quantification of CYP3A and Drug Transporters Activity in Healthy Young, Healthy Elderly and Chronic Kidney Disease Elderly Patients by a Microdose Cocktail Approach","volume":"12","author":"Rattanacheeworn","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib54","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0140-6736(76)92404-1","article-title":"Salivary phenytoin concentrations in epilepsy and in chronic renal failure","volume":"2","author":"Reynolds","year":"1976","journal-title":"Lancet"},{"key":"10.1124\/dmd.122.000967_bib55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/dmd.114.059246","article-title":"HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes","volume":"43","author":"Rubin","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.000967_bib56","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1681\/ASN.2017030361","article-title":"Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling","volume":"29","author":"Santana Machado","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.122.000967_bib57","doi-asserted-by":"crossref","first-page":"475","DOI":"10.18433\/J3M89Q","article-title":"Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver","volume":"17","author":"Sato","year":"2014","journal-title":"J Pharm Pharm Sci"},{"key":"10.1124\/dmd.122.000967_bib58","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1208\/s12248-014-9626-3","article-title":"Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients","volume":"16","author":"Sayama","year":"2014","journal-title":"AAPS J"},{"key":"10.1124\/dmd.122.000967_bib59","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/bi901786x","article-title":"The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor","volume":"49","author":"Schroeder","year":"2010","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.122.000967_bib60","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/clpt.2009.247","article-title":"Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease","volume":"87","author":"Sun","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100184","article-title":"Sensitive UHPLC-MS\/MS quantification method for 4\u03b2- and 4\u03b1-hydroxycholesterol in plasma for accurate CYP3A phenotyping","volume":"63","author":"Suzuki","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1124\/dmd.122.000967_bib62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.biopha.2011.04.031","article-title":"Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport","volume":"65","author":"Svoboda","year":"2011","journal-title":"Biomed Pharmacother"},{"key":"10.1124\/dmd.122.000967_bib63","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/psp4.12566","article-title":"Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population","volume":"9","author":"Takita","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib64","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cpt.2672","article-title":"Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease","volume":"112","author":"Takita","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib65","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/cpt.807","article-title":"Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP","volume":"103","author":"Tan","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/cpt.1205","article-title":"Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates","volume":"105","author":"Tan","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib67","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/cpt.2642","article-title":"Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1\/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose Adjustment","volume":"112","author":"Tan","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cpt.1998","article-title":"A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment","volume":"109","author":"Tatosian","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib69","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.ajkd.2014.09.015","article-title":"Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms","volume":"65","author":"Thomson","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/dmd.122.000967_bib70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.yrtph.2013.10.006","article-title":"Effect of uremic serum and uremic toxins on drug metabolism in human microsomes","volume":"68","author":"Volpe","year":"2014","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1124\/dmd.122.000967_bib71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cpt.337","article-title":"Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4\/5","volume":"100","author":"Yoshida","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.122.000967_bib72","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/clpt.2008.208","article-title":"Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications","volume":"85","author":"Zhang","year":"2009","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.000967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:09:50Z","timestamp":1768572590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624010365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0090955624010365"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.000967","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Roles of Uremic Toxins and Inflammatory Cytokines in the Alteration of Hepatic Drug Disposition in Patients with Kidney Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.000967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}